Study to Evaluate the Safety and Tolerability of GBT440 Administered to Subjects With IPF
Status:
Completed
Trial end date:
2017-11-01
Target enrollment:
Participant gender:
Summary
This study is a randomized, double-blind, placebo-controlled trial in which eligible IPF
subjects will be randomized to receive GBT440 or Placebo orally daily.